B. Kilhovd

发表

Use of Fish Oils Appears to Reduce Infarct Size as Estimated from Peak Creatine Kinase and Lactate Dehydrogenase Activities

P. Urdal, M. Abdelnoor, K. Landmark, 1998, Cardiology.

Eating fish may reduce infarct size and the occurrence of Q wave infarcts

M. Abdelnoor, K. Landmark, B. Kilhovd, 1998, European Journal of Clinical Nutrition.

Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

K. Birkeland, T. J. Berg, K. Hanssen, 1999, Diabetes care.

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study

S. Madsbad, I. Lager, B. Kilhovd, 2001, Diabetic medicine : a journal of the British Diabetic Association.

Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study

M. Laakso, S. Lehto, T. Rönnemaa, 2007, Diabetologia.

Fibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans

A. Svindland, J. Berg, K. Hanssen, 2011, Diabetes & vascular disease research.

Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women.

M. Laakso, S. Lehto, T. Rönnemaa, 2009, Atherosclerosis.

Angiotensin-Converting Enzyme Inhibition Influences Serum Levels of Advanced Glycation End Products in Patients with Coronary Artery Disease: Results from a HOPE Substudy

I. Seljeflot, Å. Reikvam, B. Kilhovd, 2003, Heart Drug.

High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men: A Population-Based 18-Year Follow-Up Study

M. Laakso, S. Lehto, T. Rönnemaa, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus.

E. Agardh, C. Agardh, L. Sandvik, 2006, Metabolism: clinical and experimental.

[Hypoglycemic treatment of type 2 diabetes].

K. Birkeland, B. Kilhovd, P. Thorsby, 2000, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Time course of specific AGEs during optimised glycaemic control in type 2 diabetes.

B. Wolffenbuttel, G. Rondas-Colbers, P. Torjesen, 2004, The Netherlands journal of medicine.

Infarct Size as Estimated from Peak Creatine Kinase and Lactate Dehydrogenase Is Probably Reduced in Patients Using Calcium Antagonists at the Onset of Symptoms

M. Abdelnoor, K. Landmark, B. Kilhovd, 1997, Cardiovascular Drugs and Therapy.

Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes.

Paul J Thornalley, K. Birkeland, M. Brownlee, 2003, Metabolism: clinical and experimental.

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia

O. Johansen, B. Kilhovd, A. Jørgensen, 2008, Vascular health and risk management.

Heterogeneity of non‐insulin‐dependent diabetes expressed as variability in insulin sensitivity, β‐cell function and cardiovascular risk profile

K. Hanssen, P. Torjesen, B. Kilhovd, 2003, Diabetic medicine : a journal of the British Diabetic Association.

Evaluating categorisation and clinical relevance of drug-related problems in medication reviews

V. Hjellvik, H. Blix, A. Granås, 2010, Pharmacy World & Science.

A pilot study testing the feasibility of skin temperature monitoring to reduce recurrent foot ulcers in patients with diabetes – a randomized controlled trial

I. Holme, K. Hvaal, B. Kilhovd, 2015, BMC Endocrine Disorders.